The pharmacokinetics of ketoconazole administered as either a commercially prepared suspension or as a crushed tablet in applesauce were studied in 12 children. The mean peak plasma concentration of ketoconazole and the area under the plasma time-concentration curve were approximately twofold greater with the suspension than with the crushed tablets. Ketoconazole, a recently licensed synthetic dioxolane imidazole, has a wide spectrum of activity against Candida species, dermatophytes, and some fungi that cause invasive disease (2). Indications for its therapeutic use include superficial dermatophyte infections, onychomycosis, chronic mucocutaneous candidiasis, and systemic histoplasmosis and coccidioidomycosis.
the various vehicles that are used to disguise the compound.
The purpose of the present study was to evaluate the bioavailability of ketoconazole as a suspension and as crushed tablets in infants and children.
The studies were conducted in the outpatient clinic of Children's Medical Center, Dallas, Tex. Infants and children with oral candidiasis and superficial dermatophytoses were eligible to participate in the study. The decision to initiate antifungal therapy was made independently of the investigators. The parents of each patient were informed of the nature of the study and the possible benefits and liabilities of receiving ketoconazole. Informed, written consent was obtained before subjects were enrolled in the study.
Twelve patients were enrolled and studied in the fasting state on two separate occasions 5 to 7 days apart: once after receiving ketoconazole powder (crushed tablet) mixed with 2 tablespoons of applesauce, and once after receiving ketoconazole suspension (supplied by Janssen Pharmaceutica, New Brunswick, N.J., as a 20-mg/ml suspension, not yet commercially available). The tablets were all crushed and powdered by the same individual. A 5-mg/kg dose was used. Blood samples were obtained through a heparin-lock and a wing-tip needle inserted into a peripheral vein just before and at 0.5, 1, 2, 4, and 6 h after the dose.
Ketoconazole concentrations were measured on a Waters liquid chromatograph (Waters Associates, Milford, Mass.), equipped with a highpressure delivery pump (M-45) and a variablewave-length detector (H1450) set at 206 nm. Separation was achieved with a hypersil-ODS reverse-phase column (Chromanetics Corp., Kensington, Md.). The mobile phase was a mixture of 60%o acetonitrile-40% 0.1 M Sorensen buffer (pH 6.6). Standards were prepared by dissolving ketoconazole powder in acetonitrile, which was then added to pooled plasma in a final concentration of from 0.1 to 10 ,ug/ml. Ketoconazole had a retention time of 5.75 min, with no interfering peaks observed from structurally related analogs.
The intraassay precision of the method was tested by measuring spiked plasma specimens, containing 0.5 or 5.0 ,Lg of ketoconazole per ml, 10 times in the same day. Concentrations averaged 0.48 + 0.08 p.g/ml (coefficient of variation, 16.7%) and 5.16 ± 0.23 ,ug/ml (coefficient of variation, 4.5%), repsectively. The interassay reproducibility of the method was tested by determining plasma ketoconazole concentrations of 0.5-and 5.0-,ug/ml doses 10 times over a 1-month period. Concentrations averaged 0.52 ± 0.1 Rg/mi ( 4 .sg/ml or greater, a level that is 2-to 10-fold higher than the minimal inhibitory concentration for most dermatophytes, Candida species, and Coccidioides immitis (2) . The significance of these findings to the clinical efficacy of the drug are unknown (3) . Additional data are required before ketoconazole suspension can be routinely recommended for the therapy of fungal infections in infants and young children.
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